

# Salim Abdool Karim

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4782683/salim-abdool-karim-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

420 papers	21,976 citations	70 h-index	136 g-index
453 ext. papers	26,397 ext. citations	10.1 avg, IF	7.47 L-index

#	Paper	IF	Citations
420	COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa.. <i>Current HIV/AIDS Reports</i> , <b>2022</b> , 19, 46	5.9	3
419	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape.. <i>Cell Host and Microbe</i> , <b>2022</b> ,	23.4	22
418	CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women.. <i>BMJ Open</i> , <b>2022</b> , 12, e052880	3	3
417	Mortality in HIV and tuberculosis patients following implementation of integrated HIV-TB treatment: Results from an open-label cluster-randomized trial.. <i>EClinicalMedicine</i> , <b>2022</b> , 44, 101298	11.3	0
416	Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression.. <i>Scientific Reports</i> , <b>2022</b> , 12, 2437	4.9	1
415	Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.. <i>Antiviral Therapy</i> , <b>2022</b> , 27, 13596535211067589	1.6	
414	Age-Restriction of a Validated Risk Scoring Tool Better Predicts HIV Acquisition in South African Women: CAPRISA 004.. <i>AIDS and Behavior</i> , <b>2022</b> , 1	4.3	
413	Public understanding of science: Communicating in the midst of a pandemic.. <i>Public Understanding of Science</i> , <b>2022</b> , 31, 282-287	3.1	2
412	SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. <b>2021</b> ,		130
411	COVID-19 in Africa: Catalyzing change for sustainable development. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003869	11.6	0
410	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1010046	7.6	3
409	Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. <i>Lancet, The</i> , <b>2021</b> ,	40	285
408	Simplifying TREATment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. <i>BMJ Open</i> , <b>2021</b> , 11, e050116	3	0
407	SARS-CoV-2 variants and ending the COVID-19 pandemic. <i>Lancet, The</i> , <b>2021</b> , 397, 952-954	40	254
406	Genital and systemic immune effects of the injectable, contraceptive norethisterone enanthate (NET-EN), in South African women. <i>American Journal of Reproductive Immunology</i> , <b>2021</b> , 86, e13411	3.8	0
405	Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. <i>Lancet, The</i> , <b>2021</b> , 397, 947-950	40	18
404	Engaging young women in Africa for PrEP use and adherence. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e122-e123	7.8	1

403	Commentary title: COVID-19 research, Africa, and global health. <i>Journal of Virus Eradication</i> , <b>2021</b> , 7, 100030	2.8	0
402	Appropriate names for COVID-19 variants. <i>Science</i> , <b>2021</b> , 371, 1215	33.3	7
401	Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. <i>Lancet, The</i> , <b>2021</b> , 397, 1263-1264	40	28
400	Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e216-e224	7.8	6
399	New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1866-1868	59.2	340
398	Institutional and behaviour-change interventions to support COVID-19 public health measures: a review by the Lancet Commission Task Force on public health measures to suppress the pandemic. <i>International Health</i> , <b>2021</b> , 13, 399-409	2.4	6
397	Epigenetic Regulation of Expression Levels and the Effect on HIV-1 Pathogenesis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 669241	8.4	2
396	Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 695201	8.4	2
395	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 1528-1531	11.6	1
394	Transient association between semen exposure and biomarkers of genital inflammation in South African women at risk of HIV infection. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25766	5.4	1
393	HIV incidence trends in Africa: young women at highest risk. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e389-e390	7.8	0
392	Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 370-380	7	15
391	Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model. <i>Journal of Investigative Medicine</i> , <b>2021</b> , 69, 28-40	2.9	2
390	Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives. <i>Biochemical and Biophysical Research Communications</i> , <b>2021</b> , 538, 221-225	3.4	6
389	Future scenarios for the COVID-19 pandemic. <i>Lancet, The</i> , <b>2021</b> , 397, 777-778	40	68
388	Impact of point-of-care testing and treatment of sexually transmitted infections and bacterial vaginosis on genital tract inflammatory cytokines in a cohort of young South African women. <i>Sexually Transmitted Infections</i> , <b>2021</b> , 97, 555-565	2.8	1
387	Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 631094	8.4	0
386	Exploring discrepant knowledge of partner sexual behaviour to inform self-risk assessment in a high HIV burdened district in rural KwaZulu-Natal. <i>Global Public Health</i> , <b>2021</b> , 1-16	3.5	

385	SARS-CoV-2 evolved during advanced HIV disease immunosuppression has Beta-like escape of vaccine and Delta infection elicited immunity. <b>2021</b> ,		12
384	Temporal Changes in Vaginal Microbiota and Genital Tract Cytokines Among South African Women Treated for Bacterial Vaginosis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 730986	8.4	1
383	A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcare clinics in South Africa. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25803	5.4	2
382	Higher mucosal antibody concentrations in women with genital tract inflammation. <i>Scientific Reports</i> , <b>2021</b> , 11, 23514	4.9	0
381	HIV pre-exposure prophylaxis implementation in Africa: some early lessons. <i>The Lancet Global Health</i> , <b>2021</b> , 9, e1634-e1635	13.6	
380	Development of a prognostic tool exploring female adolescent risk for HIV prevention and PrEP in rural South Africa, a generalised epidemic setting. <i>Sexually Transmitted Infections</i> , <b>2020</b> , 96, 47-54	2.8	3
379	The South African Response to the Pandemic. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, e95	59.2	54
378	Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. <i>Lancet HIV</i> , <b>2020</b> , 7, e229-e237	7.8	31
377	Putting women in the centre of the global HIV response is key to achieving epidemic control!. <i>Journal of the International AIDS Society</i> , <b>2020</b> , 23, e25473	5.4	5
376	Assessing a diagnosis tool for bacterial vaginosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2020</b> , 39, 1481-1485	5.3	6
375	Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. <i>BMJ Open</i> , <b>2020</b> , 10, e042247	3	8
374	Plasma concentration of injectable contraceptive correlates with reduced cervicovaginal growth factor expression in South African women. <i>Mucosal Immunology</i> , <b>2020</b> , 13, 449-459	9.2	8
373	Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape. <i>Cell Reports</i> , <b>2020</b> , 33, 108430	10.6	4
372	The Impact of Semen Exposure on the Immune and Microbial Environments of the Female Genital Tract. <i>Frontiers in Reproductive Health</i> , <b>2020</b> , 2,	1.4	3
371	Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1274	8.4	1
370	COVID-19 affects HIV and tuberculosis care. <i>Science</i> , <b>2020</b> , 369, 366-368	33.3	27
369	Identification of adolescent girls and young women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South Africa. <i>Scientific Reports</i> , <b>2020</b> , 10, 13017	4.9	3
368	Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly. <i>Lancet, The</i> , <b>2020</b> , 396, 1102-1124	40	70

367	Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials. <i>Current HIV/AIDS Reports</i> , <b>2020</b> , 17, 249-258	5.9	3
366	Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22 Suppl 6, e25346	5.4	16
365	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 1441	5.7	26
364	The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25300	5.4	21
363	Asymptomatic Bacterial Vaginosis in Pregnancy and Missed Opportunities for Treatment: A Cross-Sectional Observational Study. <i>Infectious Diseases in Obstetrics and Gynecology</i> , <b>2019</b> , 2019, 7808179	4.4	6
362	Who is sexually active? Using a multi-component sexual activity profile (MSAP) to explore, identify and describe sexually-active high-school students in rural KwaZulu-Natal, South Africa. <i>BMC Public Health</i> , <b>2019</b> , 19, 317	4.1	1
361	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naïve Adults in South Africa, 2000-2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , <b>2019</b> , 9, 26-34	11.3	29
360	Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	3
359	Acceptability of HIV self-testing among men and women in KwaZulu-Natal, South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2019</b> , 31, 186-192	2.2	31
358	Diminished HIV Infection of Target CD4+ T Cells in a Toll-Like Receptor 4 Stimulated Model. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1705	8.4	7
357	AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2019</b> , 14, 100-112	6.4	20
356	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. <i>BMJ Open</i> , <b>2019</b> , 9, e030283	3	8
355	HIV incidence rates in adolescent girls and young women in sub-Saharan Africa. <i>The Lancet Global Health</i> , <b>2019</b> , 7, e1470-e1471	13.6	25
354	The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	66
353	Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25381	5.4	6
352	Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal, South Africa. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1914378	10.4	17
351	Improving survival with tuberculosis & HIV treatment integration: A mini-review. <i>Indian Journal of Medical Research</i> , <b>2019</b> , 150, 131-138	2.9	2
350	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2875	8.4	14

349	IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1008064	7.6	25
348	HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. <i>Nature Communications</i> , <b>2019</b> , 10, 5227	17.4	15
347	Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	11
346	Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. <i>AIDS Research and Human Retroviruses</i> , <b>2019</b> , 35, 129-138	1.6	15
345	MouM always stay rightMUnderstanding vaginal products and the motivations for use among adolescent and young women in rural KZN. <i>Culture, Health and Sexuality</i> , <b>2019</b> , 21, 95-107	2.5	2
344	Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. <i>Nature Medicine</i> , <b>2018</b> , 24, 491-496	50.5	74
343	Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21, e25082	5.4	19
342	Integrin Expression on peripheral blood CD4 T cells predicts HIV acquisition and disease progression outcomes. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	62
341	Clinic-Based Evaluation of a Point-of-Care Creatinine Assay to Screen for Renal Impairment Among HIV-Positive Patients Receiving Tenofovir Disoproxil Fumarate. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 77, e36-e39	3.1	4
340	Acceptability of Early Antiretroviral Therapy Among South African Women. <i>AIDS and Behavior</i> , <b>2018</b> , 22, 1018-1024	4.3	16
339	The microbiome and HIV prevention strategies in women. <i>Current Opinion in HIV and AIDS</i> , <b>2018</b> , 13, 81-87.2	8.2	9
338	Beyond syndromic management: Opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196209	3.7	45
337	Expert consensus statement on the science of HIV in the context of criminal law. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21, e25161	5.4	38
336	Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200359	3.7	5
335	Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e427-e437	7.8	47
334	Case report: mechanisms of HIV elite control in two African women. <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 54	4	26
333	Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. <i>Cell Host and Microbe</i> , <b>2018</b> , 23, 845-854.e6	23.4	55
332	Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression. <i>Clinical Immunology</i> , <b>2018</b> , 195, 127-138	9	17



331	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1006987	7.6	49
330	Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e400-e404	7.8	44
329	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. <i>Cell Reports</i> , <b>2018</b> , 25, 3123-3135.e6	10.6	17
328	HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. <i>Cell Host and Microbe</i> , <b>2018</b> , 24, 593-599.e3	23.4	17
327	Exploratory analysis of the ecological variables associated with sexual health profiles in high-risk, sexually-active female learners in rural KwaZulu-Natal. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195107	3.7	1
326	Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. <i>Nature Communications</i> , <b>2018</b> , 9, 4136	17.4	6
325	Optimising the accuracy of HIV drug resistance assays. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e608-e609	7.8	
324	CAPRISA 003: Timing of Antiretroviral Initiation in HIV-TB Co-infected Patients—the SAPiT Trial <b>2017</b> , 107-120		
323	Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	10
322	Secrecy, empowerment and protection: positioning PrEP in KwaZulu-Natal, South Africa. <i>Culture, Health and Sexuality</i> , <b>2017</b> , 19, 1268-1285	2.5	15
321	Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e41-e50	7.8	158
320	Interleukin 1-Beta (IL-1) Production by Innate Cells Following TLR Stimulation Correlates With TB Recurrence in ART-Treated HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 74, 213-220	3.1	12
319	Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75 Suppl 1, S17-S26	3.1	63
318	Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. <i>Science</i> , <b>2017</b> , 356, 938-945	33.3	237
317	Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 76, 43-47	3.1	4
316	Trump's "global gag rule": implications for human rights and global health. <i>The Lancet Global Health</i> , <b>2017</b> , 5, e387-e389	13.6	14
315	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	59
314	Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women. <i>Journal of Immunology</i> , <b>2017</b> , 198, 1220-1228	5.3	12

313	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006148	7.6	36
312	Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol. <i>Implementation Science</i> , <b>2017</b> , 12, 129	8.4	18
311	Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. <i>Aids</i> , <b>2017</b> , 31, 2199-2209	3.5	11
310	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	65
309	Early evolution of human leucocyte antigen-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C-infected women. <i>Aids</i> , <b>2017</b> , 31, 191-197	3.5	1
308	Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 74, 318-325	3.1	31
307	Closing the NIH Fogarty Center threatens US and global health. <i>Lancet, The</i> , <b>2017</b> , 390, 451	4.0	2
306	Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	26
305	Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 819-826	11.6	10
304	Assessing progress with HIV incidence in national cohorts. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e56-e58	7.8	2
303	Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 79-82	11.6	28
302	Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2017</b> , 29, 734-740	2.2	6
301	Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREATment and Monitoring (STREAM) study. <i>BMJ Open</i> , <b>2017</b> , 7, e017507	3.7	16
300	Governmental Support of Research <b>2017</b> , 679-705		0
299	High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184124	3.7	12
298	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006074	7.6	30
297	Rolling Out of Tenofovir Gel in Family Planning Clinics: The CAPRISA 008 Implementation Trial <b>2017</b> , 57-75		1
296	The Impact of Conditional Cash Transfers in Reducing HIV in Adolescent Girls and Boys (RHIVA): The CAPRISA 007 Matched Pair, Cluster Randomised Controlled Trial <b>2017</b> , 77-89		3



295	Scaling up TB-HIV Integration in Public Health Clinics: Translating Research Findings into Practice <b>2017</b> , 121-134		
294	Prevention Clinical Trials: Highlights of Evidence and Research <b>2017</b> , 1-11		
293	Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 287-293	1.6	1
292	Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. <i>Mucosal Immunology</i> , <b>2016</b> , 9, 194-205	9.2	137
291	Combination HIV prevention options for young women in Africa. <i>African Journal of AIDS Research</i> , <b>2016</b> , 15, 109-21	1.8	24
290	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , <b>2016</b> , 12, 196-207	8.8	28
289	Metabolic Syndrome After HIV Acquisition in South African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 73, 438-445	3.1	17
288	Is the UNAIDS target sufficient for HIV control in Botswana?. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e195-6	7.8	4
287	Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. <i>Immunity</i> , <b>2016</b> , 44, 391-405	32.3	99
286	Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. <i>Mucosal Immunology</i> , <b>2016</b> , 9, 821-833	9.2	13
285	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , <b>2016</b> , 14, 43-54	10.6	45
284	Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection. <i>Sexually Transmitted Infections</i> , <b>2016</b> , 92, 186-93	2.8	36
283	Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. <i>Contraception</i> , <b>2016</b> , 93, 25-31	2.5	11
282	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , <b>2016</b> , 90, 76-91	6.6	151
281	Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 27	4	10
280	High Burden of Human Papillomavirus (HPV) Infection among Young Women in KwaZulu-Natal, South Africa. <i>PLoS ONE</i> , <b>2016</b> , 11, e0146603	3.7	27
279	Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155668	3.7	3
278	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005742	7.6	61

277	Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?. <i>PLoS Biology</i> , <b>2016</b> , 14, e1002372	9.7	5
276	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005520	7.6	106
275	Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. <i>Aids</i> , <b>2016</b> , 30, 1005-14	3.5	15
274	Diagnostic Accuracy of the Point-of-Care Xpert HIV-1 Viral Load Assay in a South African HIV Clinic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 72, e45-8	3.1	34
273	Association of Polymorphisms in the Regulatory Region of the Cyclophilin a Gene (PPIA) with Gene Expression and HIV/AIDS Disease Progression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 72, 465-73	3.1	6
272	Factors Driving the HIV Epidemic in Southern Africa. <i>Current HIV/AIDS Reports</i> , <b>2016</b> , 13, 158-69	5.9	26
271	Social Context of Adherence in an Open-Label 1% Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa. <i>AIDS and Behavior</i> , <b>2016</b> , 20, 2682-2691	4.3	11
270	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. <i>Journal of Virology</i> , <b>2016</b> , 90, 10220-10235	6.6	21
269	Individualised motivational counselling to enhance adherence to antiretroviral therapy is not superior to didactic counselling in South African patients: findings of the CAPRISA 058 randomised controlled trial. <i>AIDS and Behavior</i> , <b>2015</b> , 19, 145-56	4.3	17
268	HIV-1 Superinfection Resembles Primary Infection. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 904-8	7	11
267	Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 530-9	59.2	63
266	Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype. <i>Journal of Immunology</i> , <b>2015</b> , 195, 2273-2281	5.3	20
265	Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive. <i>Journal of Reproductive Immunology</i> , <b>2015</b> , 110, 14-21	4.2	28
264	Genital inflammation and the risk of HIV acquisition in women. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 260-9	11.6	239
263	Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001778	11.6	145
262	Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. <i>AIDS and Behavior</i> , <b>2015</b> , 19, 1305-16	4.3	31
261	HIV-positive status disclosure in patients in care in rural South Africa: implications for scaling up treatment and prevention interventions. <i>AIDS and Behavior</i> , <b>2015</b> , 19, 322-9	4.3	18
260	Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. <i>Journal of Immunology</i> , <b>2015</b> , 194, 4371-8	5.3	58

259	Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 754-9	7	21
258	Innate Antibacterial Activity in Female Genital Tract Secretions Is Associated with Increased Risk of HIV Acquisition. <i>AIDS Research and Human Retroviruses</i> , <b>2015</b> , 31, 1153-9	1.6	15
257	Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E4762-71	11.5	37
256	Defeating AIDS--advancing global health. <i>Lancet, The</i> , <b>2015</b> , 386, 171-218	40	204
255	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , <b>2015</b> , 21, 1332-6	50.5	154
254	Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 1461-6	7	6
253	Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 297-306	1.6	9
252	Challenges with participant reimbursement: experiences from a post-trial access study. <i>Journal of Medical Ethics</i> , <b>2015</b> , 41, 909-13	2.5	5
251	Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 69, 576-84	3.1	8
250	Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. <i>BMC Public Health</i> , <b>2015</b> , 15, 1149	4.1	27
249	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on $\Delta\Delta$ for replication. <i>Retrovirology</i> , <b>2015</b> , 12, 54	3.6	18
248	Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 69, 264-9	3.1	59
247	Antibodies for HIV prevention in young women. <i>Current Opinion in HIV and AIDS</i> , <b>2015</b> , 10, 183-9	4.2	8
246	Relationship between female genital tract infections, mucosal interleukin-17 production and local T helper type 17 cells. <i>Immunology</i> , <b>2015</b> , 146, 557-67	7.8	35
245	Trends in HIV Prevalence in Pregnant Women in Rural South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 70, 289-95	3.1	39
244	Adolescent girls and young women: key populations for HIV epidemic control. <i>Journal of the International AIDS Society</i> , <b>2015</b> , 18, 19408	5.4	256
243	Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131906	3.7	17
242	HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 68, 55-61	3.1	10

241	Tenofovir Gel to Prevent HSV-2 Infection. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1980-1	59.2	1
240	Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 1916-20	7	12
239	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , <b>2014</b> , 509, 55-62	50.4	537
238	TRIM5 $\alpha$ and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. <i>Journal of Virology</i> , <b>2014</b> , 88, 4291-303	6.6	17
237	Retrospective. Nelson R. Mandela (1918-2013). <i>Science</i> , <b>2014</b> , 343, 150	33.3	3
236	Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. <i>Sexually Transmitted Infections</i> , <b>2014</b> , 90, 580-7	2.8	112
235	Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. <i>Cell Host and Microbe</i> , <b>2014</b> , 16, 304-13	23.4	99
234	Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: association with disease progression and influence of immune pressure. <i>Virology</i> , <b>2014</b> , 468-470, 214-225	3.6	15
233	Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. <i>AIDS and Behavior</i> , <b>2014</b> , 18, 849-54	4.3	39
232	Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial. <i>AIDS and Behavior</i> , <b>2014</b> , 18, 820-5	4.3	6
231	Monitoring microbicide gel use with real-time notification of the container opening events: results of the CAPRISA Wisebag study. <i>AIDS and Behavior</i> , <b>2014</b> , 18, 833-40	4.3	9
230	Adherence in the CAPRISA 004 tenofovir gel microbicide trial. <i>AIDS and Behavior</i> , <b>2014</b> , 18, 811-9	4.3	21
229	Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. <i>AIDS and Behavior</i> , <b>2014</b> , 18, 841-8	4.3	20
228	Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study. <i>AIDS and Behavior</i> , <b>2014</b> , 18, 826-32	4.3	9
227	The preventive misconception: experiences from CAPRISA 004. <i>AIDS and Behavior</i> , <b>2014</b> , 18, 1746-52	4.3	8
226	Impact of antiretroviral therapy on health-related quality of life among South African women in the CAPRISA 002 acute infection study. <i>AIDS and Behavior</i> , <b>2014</b> , 18, 1801-7	4.3	14
225	Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey. <i>Sexually Transmitted Infections</i> , <b>2014</b> , 90, 620-6	2.8	41
224	The HIV epidemic in Southern Africa - Is an AIDS-free generation possible?. <i>Current HIV/AIDS Reports</i> , <b>2014</b> , 11, 99-108	5.9	18

223	Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 161-9	1.6	14
222	High rates of tuberculosis in patients accessing HAART in rural South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2014</b> , 65, 438-46	3.1	13
221	Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2014</b> , 18, 147-54	2.1	26
220	Implementation of adolescent-friendly voluntary medical male circumcision using a school based recruitment program in rural KwaZulu-Natal, South Africa. <i>PLoS ONE</i> , <b>2014</b> , 9, e96468	3.7	31
219	HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. <i>PLoS ONE</i> , <b>2014</b> , 9, e101863	3.7	26
218	Inclusion of adolescent girls in HIV prevention research - an imperative for an AIDS-free generation. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19075	5.4	11
217	Meeting the sexual and reproductive health needs of high-school students in South Africa: experiences from rural KwaZulu-Natal. <i>South African Medical Journal</i> , <b>2014</b> , 104, 687-90	1.5	9
216	Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2014</b> , 26, 1521-5	2.2	13
215	Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. <i>Trials</i> , <b>2014</b> , 15, 496	2.8	9
214	Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 844-8	9.7	12
213	HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women. <i>Sexually Transmitted Infections</i> , <b>2014</b> , 90, 363-9	2.8	30
212	Low rifampicin concentrations in tuberculosis patients with HIV infection. <i>Journal of Infection in Developing Countries</i> , <b>2014</b> , 8, 987-93	2.3	25
211	Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, A20-A21	1.6	1
210	Appeal to global donors to save the Treatment Action Campaign. <i>Lancet, The</i> , <b>2014</b> , 384, e62	4.0	1
209	HIV infection in high school students in rural South Africa: role of transmissions among students. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, 956-65	1.6	15
208	Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point. <i>Journal of Virology</i> , <b>2014</b> , 88, 1819-24	6.6	32
207	Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. <i>Sexually Transmitted Diseases</i> , <b>2014</b> , 41, 123-8	2.4	64
206	Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women. <i>Sexually Transmitted Diseases</i> , <b>2014</b> , 41, 674-9	2.4	17

205	Rapid disease progression in HIV-1 subtype C-infected South African women. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 1322-31	11.6	35
204	Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. <i>Retrovirology</i> , <b>2014</b> , 11, 69	3.6	19
203	Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 500-9	7	76
202	The need for multipurpose prevention technologies in sub-Saharan Africa. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2014</b> , 121 Suppl 5, 27-34	3.7	20
201	Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2014</b> , 121 Suppl 5, 53-61	3.7	7
200	Mervyn W. Susser - his contributions to the acquired immune deficiency syndrome response in South Africa. <i>Paediatric and Perinatal Epidemiology</i> , <b>2014</b> , 28, 473-5	2.7	
199	Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort study. <i>AIDS and Behavior</i> , <b>2014</b> , 18, 1114-23	4.3	13
198	Microbicides for prevention of HIV infection: clinical efficacy trials. <i>Current Topics in Microbiology and Immunology</i> , <b>2014</b> , 383, 97-115	3.3	7
197	Translating Pre-Exposure Prophylaxis Evidence into Practice and Public Health Impact <b>2014</b> , 29-40		1
196	The global HIV epidemic: current status and challenges. <i>Current HIV/AIDS Reports</i> , <b>2013</b> , 10, 111-2	5.9	8
195	Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. <i>Journal of Virology</i> , <b>2013</b> , 87, 7218-33	6.6	93
194	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. <i>Virology Journal</i> , <b>2013</b> , 10, 347	6.1	12
193	Microbicides for the prevention of sexually transmitted HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , <b>2013</b> , 11, 13-23	5.5	10
192	HIV pre-exposure prophylaxis in injecting drug users. <i>Lancet, The</i> , <b>2013</b> , 381, 2060-2	4.0	13
191	Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. <i>Vaccine</i> , <b>2013</b> , 31 Suppl 2, B204-8	4.1	22
190	Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial. <i>Antiviral Research</i> , <b>2013</b> , 99, 405-8	10.8	0
189	Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 294-8	3.1	6
188	Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003738	7.6	147



187	The changing epidemiology of HIV in 2013. <i>Current Opinion in HIV and AIDS</i> , <b>2013</b> , 8, 306-10	4.2	68
186	When to start antiretroviral therapy during tuberculosis treatment?. <i>Current Opinion in Infectious Diseases</i> , <b>2013</b> , 26, 35-42	5.4	34
185	Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. <i>Journal of Virology</i> , <b>2013</b> , 87, 4882-94	6.6	55
184	Topical microbicides--what's new?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63 Suppl 2, S144-9	3.1	16
183	Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression. <i>Aids</i> , <b>2013</b> , 27, 507-18	3.5	11
182	Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 120-5	3.1	18
181	Changes in Natural Killer cell activation and function during primary HIV-1 Infection. <i>PLoS ONE</i> , <b>2013</b> , 8, e53251	3.7	41
180	Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. <i>PLoS ONE</i> , <b>2013</b> , 8, e56400	3.7	7
179	No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. <i>PLoS ONE</i> , <b>2013</b> , 8, e71758	3.7	9
178	Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. <i>PLoS ONE</i> , <b>2013</b> , 8, e78818	3.7	30
177	Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 301-10	1.6	18
176	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 380-93	15.9	141
175	Empowering women in human immunodeficiency virus prevention. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2012</b> , 26, 487-93	4.6	12
174	Overview of microbicides for the prevention of human immunodeficiency virus. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2012</b> , 26, 427-39	4.6	29
173	Implementing microbicides in low-income countries. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2012</b> , 26, 495-501	4.6	8
172	The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. <i>Annals of Internal Medicine</i> , <b>2012</b> , 157, 313-24	8	87
171	Antiretroviral prophylaxis for HIV prevention reaches a key milestone. <i>Lancet, The</i> , <b>2012</b> , 379, 2047-8	40	8
170	Health in South Africa: changes and challenges since 2009. <i>Lancet, The</i> , <b>2012</b> , 380, 2029-43	40	319

169	Sustainability of task-shifting for antiretroviral treatment. <i>Lancet, The</i> , <b>2012</b> , 380, 1907-8; author reply 1908	40	5
168	HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials. <i>AIDS and Behavior</i> , <b>2012</b> , 16, 1870-6	4.3	46
167	Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. <i>Nature Medicine</i> , <b>2012</b> , 18, 1688-92	50.5	234
166	HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. <i>BMC Public Health</i> , <b>2012</b> , 12, 231	4.1	29
165	HIV prevention <b>2012</b> , 113-121		
164	The development of CD4 binding site antibodies during HIV-1 infection. <i>Journal of Virology</i> , <b>2012</b> , 86, 7588-95	6.6	105
163	CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 35-40	7	15
162	The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 689-95	2.8	42
161	Temporal association of HLA-B*81:01- and HLA-B*39:10-mediated HIV-1 p24 sequence evolution with disease progression. <i>Journal of Virology</i> , <b>2012</b> , 86, 12013-24	6.6	16
160	Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 194-203	7	62
159	Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 1931-5	7	20
158	Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness. <i>Journal of Virology</i> , <b>2012</b> , 86, 13423-33	6.6	9
157	Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 6-14	7	131
156	Clinical decisions. Preexposure prophylaxis for HIV prevention. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 462-5	59.2	8
155	Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 993-1001	7	116
154	Increased memory differentiation is associated with decreased polyfunctionality for HIV but not for cytomegalovirus-specific CD8+ T cells. <i>Journal of Immunology</i> , <b>2012</b> , 189, 3838-47	5.3	17
153	A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 695-715	5.9	22
152	Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. <i>Vaccine Journal</i> , <b>2012</b> , 19, 1651-60		49

151	Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial. <i>Aids</i> , <b>2012</b> , 26, 2261; author reply 2262-3	3.5	4
150	An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. <i>Clinical Trials</i> , <b>2012</b> , 9, 377-84	2.2	2
149	Design challenges facing clinical trials of the effectiveness of new HIV-prevention technologies. <i>Aids</i> , <b>2012</b> , 26, 529-32	3.5	7
148	Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. <i>Aids</i> , <b>2012</b> , 26, 1745-53	3.5	13
147	Preservation HIV-1-specific IFN $\gamma$ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 60, 124-7	3.1	13
146	Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. <i>Journal of Virology</i> , <b>2011</b> , 85, 3128-41	6.6	128
145	Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. <i>Journal of Virology</i> , <b>2011</b> , 85, 11502-19	6.6	148
144	Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial. <i>Contemporary Clinical Trials</i> , <b>2011</b> , 32, 333-8	2.3	22
143	Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. <i>Lancet Infectious Diseases, The</i> , <b>2011</b> , 11, 525-32	25.5	183
142	HIV prevention transformed: the new prevention research agenda. <i>Lancet, The</i> , <b>2011</b> , 378, 269-78	40	201
141	Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. <i>Lancet, The</i> , <b>2011</b> , 378, 279-81	40	189
140	Antiretroviral prophylaxis: a defining moment in HIV control. <i>Lancet, The</i> , <b>2011</b> , 378, e23-5	40	76
139	Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. <i>Aids</i> , <b>2011</b> , 25, 957-66	3.5	190
138	Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. <i>Obstetrics and Gynecology</i> , <b>2011</b> , 118, 895-904	4.9	31
137	Stigma impedes AIDS prevention. <i>Nature</i> , <b>2011</b> , 474, 29-31	50.4	20
136	Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. <i>Trials</i> , <b>2011</b> , 12, 67	2.8	26
135	The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. <i>Journal of Virology</i> , <b>2011</b> , 85, 4828-40	6.6	348
134	Initiating antiretrovirals during tuberculosis treatment: a drug safety review. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 559-74	4.1	15

133	Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, 1248-56	11.6	62
132	Integration of antiretroviral therapy with tuberculosis treatment. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1492-501	59.2	395
131	Virological and immunological factors associated with HIV-1 differential disease progression in HLA-B 58:01-positive individuals. <i>Journal of Virology</i> , <b>2011</b> , 85, 7070-80	6.6	21
130	The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. <i>Sexually Transmitted Infections</i> , <b>2011</b> , 87, 646-53	2.8	21
129	HIV-Associated Tuberculosis. <i>Clinical and Developmental Immunology</i> , <b>2011</b> , 2011,		11
128	Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. <i>International Journal of Epidemiology</i> , <b>2011</b> , 40, 922-30	7.8	104
127	Case records of the Massachusetts General Hospital. Case 15-2011. A 19-year-old South African woman with headache, fatigue, and vaginal discharge. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1956-64	59.2	64
126	Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. <i>Aids</i> , <b>2011</b> , 25, 1711-9	3.5	20
125	Experience in international clinical research: the HIV Prevention Trials Network. <i>Clinical Investigation</i> , <b>2011</b> , 1, 1609-1618		12
124	Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 58, 207-10	3.1	42
123	Short communication decreased incidence of dual infections in South african subtype C-infected women compared to a cohort ten years earlier. <i>AIDS Research and Human Retroviruses</i> , <b>2011</b> , 27, 1167-72	1.6	5
122	Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. <i>Journal of Virology</i> , <b>2011</b> , 85, 208-16	6.6	62
121	Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. <i>Journal of Virology</i> , <b>2011</b> , 85, 7719-29	6.6	50
120	Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. <i>PLoS ONE</i> , <b>2011</b> , 6, e23532	3.7	123
119	AIDS research must link to local policy. <i>Nature</i> , <b>2010</b> , 463, 733-4	50.4	12
118	The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. <i>South African Medical Journal</i> , <b>2010</b> , 100, 808-9	1.5	7
117	Inclusion of Adolescent Women in Microbicide Trials: A Public Health Imperative!. <i>Public Health Ethics</i> , <b>2010</b> , 3, 39-50	1.8	11
116	Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression. <i>Journal of Virology</i> , <b>2010</b> , 84, 12018-29	6.6	22

115	HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 281-5	9.7	6
114	Preventing HIV infection in women: a global health imperative. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50 Suppl 3, S122-9	11.6	81
113	Uptake of provider-initiated HIV testing and counseling among women attending an urban sexually transmitted disease clinic in South Africa - missed opportunities for early diagnosis of HIV infection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2010</b> , 22, 533-7	2.2	30
112	APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. <i>Aids</i> , <b>2010</b> , 24, 195-204	3.5	53
111	Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. <i>Science</i> , <b>2010</b> , 329, 1168-74	33.3	1964
110	Timing of initiation of antiretroviral drugs during tuberculosis therapy. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 697-706	59.2	519
109	Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. <i>Aids</i> , <b>2010</b> , 24, 819-31	3.5	146
108	Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure. <i>Virology</i> , <b>2010</b> , 396, 213-25	3.6	25
107	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. <i>Virology</i> , <b>2010</b> , 402, 187-96	3.6	82
106	Screening for Window-period acute HIV infection among pregnant women in rural South Africa. <i>HIV Medicine</i> , <b>2010</b> , 11, 661-5	2.7	26
105	Re: "Enhancement of HIV infection by cellulose sulfate," by Tao et al. <i>AIDS Research and Human Retroviruses</i> , <b>2009</b> , 25, 373; author reply 375-6	1.6	1
104	Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 199, 1657-63	7	41
103	Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point. <i>Journal of Immunology</i> , <b>2009</b> , 182, 4751-61	5.3	68
102	Commentary: Spatial clustering of HIV infection: providing clues for effective HIV prevention. <i>International Journal of Epidemiology</i> , <b>2009</b> , 38, 1016-7	7.8	7
101	Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. <i>Journal of Virology</i> , <b>2009</b> , 83, 3556-67	6.6	306
100	Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. <i>PLoS Pathogens</i> , <b>2009</b> , 5, e1000598	7.6	184
99	Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 200, 448-52	7	57
98	Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. <i>Journal of Virology</i> , <b>2009</b> , 83, 11265-74	6.6	84

97	Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. <i>Journal of Virology</i> , <b>2009</b> , 83, 470-8	6.6	54
96	Salim "Slim" Abdool Karim: attacking AIDS in South Africa. Interview by Amy Maxmen. <i>Journal of Experimental Medicine</i> , <b>2009</b> , 206, 2306-7	16.6	
95	Scientists stand by decision to join Mbeki's AIDS panel. <i>Nature</i> , <b>2009</b> , 457, 379	50.4	1
94	Disclosure of HIV status: Experiences of Patients Enrolled in an Integrated TB and HAART Pilot Programme in South Africa. <i>African Journal of AIDS Research</i> , <b>2009</b> , 8, 1-6	1.8	10
93	HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. <i>Lancet, The</i> , <b>2009</b> , 374, 921-33	40	349
92	Achieving the health Millennium Development Goals for South Africa: challenges and priorities. <i>Lancet, The</i> , <b>2009</b> , 374, 1023-1031	40	165
91	PRO 2000: next steps for microbicide development. <i>Future Virology</i> , <b>2009</b> , 4, 317-320	2.4	2
90	Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges. <i>HIV Therapy</i> , <b>2009</b> , 3, 3-6		27
89	Interventions with youth in high-prevalence areas <b>2009</b> , 407-443		5
88	Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection. <i>Virology Journal</i> , <b>2008</b> , 5, 141	6.1	4
87	Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. <i>Journal of Virology</i> , <b>2008</b> , 82, 12449-63	6.6	452
86	Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. <i>Journal of Virology</i> , <b>2008</b> , 82, 115-25	6.6	101
85	Apnea and its possible relationship to immunization in ex-premature infants. <i>Vaccine</i> , <b>2008</b> , 26, 3410-3	4.1	13
84	The influence of AIDS stigma and discrimination and social cohesion on HIV testing and willingness to disclose HIV in rural KwaZulu-Natal, South Africa. <i>Global Public Health</i> , <b>2008</b> , 3, 351-365	3.5	36
83	HIV risk behaviors in sub-Saharan Africa and Northern Thailand: baseline behavioral data from Project Accept. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2008</b> , 49, 309-19	3.1	37
82	Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 710-4	7	60
81	Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. <i>PLoS Pathogens</i> , <b>2008</b> , 4, e1000033	7.6	118
80	The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. <i>Journal of Virology</i> , <b>2008</b> , 82, 1860-9	6.6	132



79	HIV Transmission and its Prevention in Africa <b>2008</b> , 565-575		
78	Anaemia in acute HIV-1 subtype C infection. <i>PLoS ONE</i> , <b>2008</b> , 3, e1626	3.7	14
77	Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. <i>PLoS ONE</i> , <b>2008</b> , 3, e1954	3.7	150
76	Global epidemiology of HIV-AIDS. <i>Infectious Disease Clinics of North America</i> , <b>2007</b> , 21, 1-17, vii	6.5	18
75	Diverse approaches useful for microbicide trials. <i>Nature</i> , <b>2007</b> , 449, 24	50.4	8
74	Opportunities for treating sexually transmitted infections and reducing HIV risk in rural South Africa. <i>Journal of Advanced Nursing</i> , <b>2007</b> , 60, 377-83	3.1	15
73	Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. <i>BMC Pediatrics</i> , <b>2007</b> , 7, 13	2.6	148
72	Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. <i>Journal of Virology</i> , <b>2007</b> , 81, 6187-96	6.6	242
71	Response to Brown et al., Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe <i>Aids</i> , <b>2007</b> , 21, 2356-7	3.5	
70	Utilizing nucleic acid amplification to identify acute HIV infection. <i>Aids</i> , <b>2007</b> , 21, 653-5	3.5	11
69	Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. <i>AIDS Research and Human Retroviruses</i> , <b>2007</b> , 23, 316-21	1.6	23
68	Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. <i>Journal of the Association of Nurses in AIDS Care</i> , <b>2007</b> , 18, 78-82	1.6	20
67	HIV incidence estimates are key to understanding the changing HIV epidemic in South Africa. <i>South African Medical Journal</i> , <b>2007</b> , 97, 190	1.5	2
66	Durban 2000 to Toronto 2006: the evolving challenges in implementing AIDS treatment in Africa. <i>Aids</i> , <b>2006</b> , 20, N7-9	3.5	6
65	Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings. <i>Aids</i> , <b>2006</b> , 20, 302-3	3.5	4
64	Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. <i>Journal of Virology</i> , <b>2006</b> , 80, 11776-90	6.6	311
63	TB treatment outcomes following directly-observed treatment at an urban outpatient specialist TB facility in South Africa. <i>Tropical Doctor</i> , <b>2006</b> , 36, 23-5	0.9	6
62	HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. <i>Lancet, The</i> , <b>2006</b> , 368, 489-504	40	353

61	Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. <i>PLoS Medicine</i> , <b>2006</b> , 3, e180	11.6	33
60	Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 43, 219-25	3.1	24
59	Knowledge and acceptability of HAART among TB patients in Durban, South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2005</b> , 17, 767-72	2.2	10
58	Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. <i>AIDS Research and Human Retroviruses</i> , <b>2005</b> , 21, 285-91	1.6	24
57	The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2005</b> , 39, 333-9	3.1	62
56	The African Experience <b>2005</b> , 351-373		0
55	Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 1355-9	7	98
54	Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. <i>Journal of Virology</i> , <b>2004</b> , 78, 3233-43	6.6	193
53	A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2004</b> , 36, 929-34	3.1	55
52	Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. <i>Journal of Immunology</i> , <b>2004</b> , 173, 4607-17	5.3	47
51	Ethical challenges in international HIV prevention research. <i>Accountability in Research</i> , <b>2004</b> , 11, 49-61	1.9	22
50	Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38 Suppl 5, S421-8	11.6	24
49	Treatment of maternal syphilis in rural South Africa: effect of multiple doses of benzathine penicillin on pregnancy loss. <i>Tropical Medicine and International Health</i> , <b>2004</b> , 9, 1216-21	2.3	19
48	Dual HIV-1 infection associated with rapid disease progression. <i>Lancet, The</i> , <b>2004</b> , 363, 619-22	4.0	163
47	Medical education after the first decade of democracy in South Africa. <i>Lancet, The</i> , <b>2004</b> , 363, 1395	4.0	8
46	Heterosexual transmission of multiple highly conserved viral variants in HIV-1 subtype C-infected seronegative women. <i>Aids</i> , <b>2004</b> , 18, 2096-8	3.5	6
45	Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. <i>Aids</i> , <b>2003</b> , 17, 321-9	3.5	78
44	Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. <i>Aids</i> , <b>2003</b> , 17, 2245-52	3.5	216

43	The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. <i>Sexually Transmitted Diseases</i> , <b>2003</b> , 30, 149-56	2.4	312
42	Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2003</b> , 34, 482-90	3.1	49
41	Antiretroviral therapy: challenges and options in South Africa. <i>Lancet, The</i> , <b>2003</b> , 362, 1499	4.0	5
40	Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. <i>AIDS Research and Human Retroviruses</i> , <b>2003</b> , 19, 133-44	1.6	103
39	The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. <i>Journal of Women's Health</i> , <b>2003</b> , 12, 655-66	3	86
38	Impact of on-site testing for maternal syphilis on treatment delays, treatment rates, and perinatal mortality in rural South Africa: a randomised controlled trial. <i>Sexually Transmitted Infections</i> , <b>2003</b> , 79, 208-13	2.8	46
37	High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversion. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 29, 531-5	3.1	41
36	Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. <i>Journal of Virology</i> , <b>2002</b> , 76, 2233-44	6.6	105
35	The evolving HIV epidemic in South Africa. <i>International Journal of Epidemiology</i> , <b>2002</b> , 31, 37-40	7.8	45
34	Incidence of Sexually Transmitted Infections among HIV-positive sex workers in KwaZulu-Natal, South Africa. <i>Sexually Transmitted Diseases</i> , <b>2002</b> , 29, 721-4	2.4	17
33	A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2002</b> , 49, 875-8	5.1	26
32	Vertical HIV transmission in South Africa: translating research into policy and practice. <i>Lancet, The</i> , <b>2002</b> , 359, 992-3	4.0	16
31	Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. <i>Lancet, The</i> , <b>2002</b> , 360, 971-7	4.0	671
30	Estimating HIV incidence rates from age prevalence data in epidemic situations. <i>Statistics in Medicine</i> , <b>2001</b> , 20, 2003-16	2.3	55
29	Conserved domains of subtype C nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. <i>AIDS Research and Human Retroviruses</i> , <b>2001</b> , 17, 1681-7	1.6	20
28	Characterization of full-length HIV type 1 subtype C sequences from South Africa. <i>AIDS Research and Human Retroviruses</i> , <b>2001</b> , 17, 1527-31	1.6	52
27	The fate of free male condoms distributed to the public in South Africa. <i>Aids</i> , <b>2001</b> , 15, 789-93	3.5	18
26	Clinical testing of microbicides: a global research priority. <i>Aids</i> , <b>2001</b> , 15, 929-30	3.5	1

25	Estimating HIV incidence rates from age prevalence data in epidemic situations <b>2001</b> , 20, 2003		2
24	Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world. <i>Aids</i> , <b>2000</b> , 14, 2553-7	3.5	32
23	Availability of condoms in urban and rural areas of KwaZulu-Natal, South Africa. <i>Sexually Transmitted Diseases</i> , <b>2000</b> , 27, 353-7	2.4	15
22	Syndrome packets and health worker training improve sexually transmitted disease case management in rural South Africa: randomized controlled trial. <i>Aids</i> , <b>2000</b> , 14, 2769-79	3.5	35
21	Inadequate treatment for sexually transmitted diseases in the South African private health sector. <i>International Journal of STD and AIDS</i> , <b>1999</b> , 10, 324-7	1.4	23
20	Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. <i>Aids</i> , <b>1999</b> , 13, 1511-5	3.5	42
19	STD syndrome packets: improving syndromic management of sexually transmitted diseases in developing countries. <i>Sexually Transmitted Diseases</i> , <b>1999</b> , 26, 152-6	2.4	10
18	HIV infection and asymptomatic sexually transmitted infections in a rural South African community. <i>International Journal of STD and AIDS</i> , <b>1998</b> , 9, 548-50	1.4	30
17	Sexually transmitted infections among sex workers in KwaZulu-Natal, South Africa. <i>Sexually Transmitted Diseases</i> , <b>1998</b> , 25, 346-9	2.4	65
16	Improving quality of sexually transmitted disease case management in rural South Africa. <i>Aids</i> , <b>1998</b> , 12, 2329-35	3.5	26
15	Sexually transmitted disease syndromes in rural South Africa. Results from health facility surveillance. <i>Sexually Transmitted Diseases</i> , <b>1998</b> , 25, 20-3	2.4	24
14	Country profile. South Africa. <i>Lancet, The</i> , <b>1997</b> , 349, 1537-45	4.0	13
13	Potential savings from generic prescribing and generic substitution in South Africa. <i>Health Policy and Planning</i> , <b>1996</b> , 11, 198-205	3.4	33
12	Sex difference in measles fatality after introduction of new measles vaccine. <i>Lancet, The</i> , <b>1994</b> , 343, 1366-7	4.0	4
11	Seroprevalence of HIV infection in rural South Africa. <i>Aids</i> , <b>1992</b> , 6, 1535-9	3.5	76
10	Household clustering and intra-household transmission patterns of hepatitis B virus infection in South Africa. <i>International Journal of Epidemiology</i> , <b>1991</b> , 20, 495-503	7.8	44
9	The prevalence and transmission of hepatitis B virus infection in urban, rural and institutionalized black children of Natal/KwaZulu, South Africa. <i>International Journal of Epidemiology</i> , <b>1988</b> , 17, 168-73	7.8	39
8	Socio-medical indicators of health in South Africa. <i>International Journal of Health Services</i> , <b>1986</b> , 16, 163-76		11

7	Overview of the book45-54	2
6	New prevention strategies under development and investigation268-282	2
5	The future of the HIV epidemic in South Africa585-590	
4	Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV	1
3	The Replication-Competent HIV-1 Latent Reservoir is Primarily Established Near the Time of Therapy Initiation	2
2	Clinical severity of COVID-19 patients admitted to hospitals during the Omicron wave in South Africa	1
1	Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa. <i>Transactions of the Royal Society of South Africa</i> ,1-4	1